| Literature DB >> 19335916 |
Jean-Frédéric Vodoz1, Vincent Cottin, Jean-Charles Glérant, Geneviève Derumeaux, Chahéra Khouatra, Anne-Sophie Blanchet, Bénédicte Mastroïanni, Jean-Yves Bayle, Jean-François Mornex, Jean-François Cordier.
Abstract
BACKGROUND: Hypoxemia is common in pulmonary hypertension (PH) and may be partly related to ventilation/perfusion mismatch, low diffusion capacity, low cardiac output, and/or right-to-left (RL) shunting.Entities:
Mesh:
Year: 2009 PMID: 19335916 PMCID: PMC2671488 DOI: 10.1186/1471-2261-9-15
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Figure 1Flowchart summarizing the selection and inclusion process. PH, pulmonary hypertension; TTCE, transthoracic contrast echocardiography.
Clinical and functional characteristics at the time of diagnosis of pulmonary hypertension.
| Age, yr | 64.0 ± 15 (25–82) |
| Sex (M/F) | 19/15 |
| Ex- or active smokers, % | 50 |
| Dyspnea NYHA class III–IV, % | 76 |
| 6-min-walk distance, m | 271 ± 116 (32–465) |
| TLC, % predicted | 89 ± 16 (51–121) |
| FEV1, % predicted | 76 ± 20 (33–117) |
| FEV1/FVC, % | 65 ± 11 (36–88) |
| DLco, % predicted | 49 ± 30 (12–113) |
| DLco/VA, % predicted | 51 ± 28 (11–113) |
| PaO2, kPa | 6.8 ± 1.3 (4.5–10.0) |
FEV1, forced expiratory volume in one second; TLC, total lung capacity; DLco, single-breath diffusing capacity of the lung for carbon monoxide; VA, alveolar volume; NYHA, New York Heart Association.
Data expressed are mean ± SD (range) for quantitative values.
Etiologic groups of pulmonary hypertension [1].
| Pulmonary arterial hypertension (group 1) | |
| Idiopathic | 6 (18%) |
| Portal hypertension | 1 (3%) |
| Associated with lung disease and/or hypoxemia (group 3) | |
| Chronic obstructive pulmonary disease | 8 (23%) |
| Interstitial lung disease | 3 (9%) |
| Combined pulmonary fibrosis and emphysema | 3 (9%) |
| Other | 2 (6%) |
| Thromboembolic obstruction (group 4) | |
| Miscellaneous (group 5) |
Data expressed are absolute values (percent of total).
Hemodynamic characteristics at the time of diagnosis of pulmonary hypertension.
| RAP, mmHg | 8 ± 4 (2–16) |
| mPAP, mmHg | 46 ± 11 (30–68) |
| PAWP, mmHg | 8 ± 3 (2–14) |
| Cardiac index, L/min/m2 | 2.2 ± 0.6 (1–3.4) |
| SvO2, % | 55.8 ± 8.5 (41–72) |
| PVR, dyn.s.cm-5 | 469 ± 275 (142–1183) |
| PVRI, dyn.s.cm-5/m2 | 819 ± 446 (262–2082) |
PAWP = pulmonary arterial wedge pressure; mPAP = mean pulmonary arterial pressure; RAP = right atrial pressure; PVR = pulmonary vascular resistance; PVRI = pulmonary vascular resistance index; SvO2 = venous oxygen saturation.
Figure 2A, Measurement of AaPO2 while breathing 100% oxygen according to the etiologic groups of patients (difference between groups was not significant by oneway analysis of variance). B, PaO2 on room air according to the etiologic groups (difference between groups was significant by Kruskal Wallis analysis, with p < 0.05; two-by-two post-hoc analysis was significant between groups 3 and 5, and group 4 by Bonferroni's multiple comparison test, p < 0.05). Group 1, pulmonary arterial hypertension; group 3, pulmonary hypertension associated with pulmonary diseases; group 4, chronic thromboembolic pulmonary hypertension; group 5, miscellaneous.